作者cozzi (冰裂疊影)
看板Bioindustry
標題[新聞] 醣質定序
時間Wed Oct 13 23:26:07 2004
學生時期覺得醣類研究相當複雜，未能建立什麼概念，今天看到這新聞還真覺得
美妙。這影響生技產業重要因素不僅在於醣類本身有醫療功效外，更能大幅改善
生技學名藥的醣基化的不確定性。
出處：
http://biz.yahoo.com/prnews/041012/netu044_1.html
標題：Momenta Pharmaceuticals' Technology Featured in Nature Reviews
內容：
請參照網址內容
延伸閱讀：
1.About Momenta
Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in
the sequencing and engineering of complex sugars for the development of
improved versions of existing drugs, the development of novel drugs and
the discovery of new biological processes. Momenta is also utilizing its
ability to sequence sugars to create technology-enabled generic products.
The Company's most advanced product candidate is M-Enoxaparin, a technology-
enabled generic version of LovenoxR. Based on its understanding of complex
sugars, Momenta has created a diversified pipeline of novel discovery and
development candidates. Momenta was founded in 2001 and is headquartered
in Cambridge, MA.
2.給生物科技加點「醣」
http://www.sciam.com.tw/circus/circusshow.asp?FDocNo=154&DocNo=245&CL=21
--
※ 發信站: 批踢踢實業坊(ptt.cc)
◆ From: 210.244.69.64